# Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan

> **NCT06717191** · PHASE4 · COMPLETED · sponsor: **Life for a Child Program, Diabetes Australia** · enrollment: 296 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** biosimilar insulin glargine

## Key facts

- **NCT ID:** NCT06717191
- **Lead sponsor:** Life for a Child Program, Diabetes Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-08-02
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717191, "Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06717191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*